The 2nd Liquid Biopsy Surveillance & Early Detection Summit offered an exceptional opportunity for networking and connecting with 150+ influential decision-makers harnessing liquid biopsies for personalized medicines.

Partners used this unique opportunity to present your innovative tools and technologies to a niche community focused on establishing robust early detection and surveillance assays in an industry poised for remarkable growth in 2023.

Biopharma are actively seeking solutions to stay informed about the latest advancements in non-invasive testing and collaborate with partners who have capabilities in: